Next Article in Journal
Genome-Wide Identification and Characterization of Maize Long-Chain Acyl-CoA Synthetases and Their Expression Profiles in Different Tissues and in Response to Multiple Abiotic Stresses
Previous Article in Journal
A Comprehensive Systematic Review Coupled with an Interacting Network Analysis Identified Candidate Genes and Biological Pathways Related to Bovine Temperament
Previous Article in Special Issue
Exploring Microorganisms Associated to Acute Febrile Illness and Severe Neurological Disorders of Unknown Origin: A Nanopore Metagenomics Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 15
Issue 8
10.3390/genes15080982
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations

by
Kabo Baruti
1,2,
Wonderful T. Choga
1,3,
Bonolo B. Phinius
1,3,
Basetsana Phakedi
1,
Lynnette Bhebhe
1,
Gorata G. A. Mpebe
1,
Patience C. Motshosi
1,
Tsholofelo Ratsoma
1,
Sikhulile Moyo
1,4,5,
Mosimanegape Jongman
1,2,
Motswedi Anderson
1,6,7 and
Simani Gaseitsiwe
1,4,*
1
Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana
2
Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana
3
School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana
4
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
5
Department of Pathology, Division of Medical Virology, Stellenbosch University, Cape Town 7535, South Africa
6
Africa Health Research Institute (AHRI), Durban 4013, South Africa
7
The Francis Crick Institute, London NW1 2BE, UK
*
Author to whom correspondence should be addressed.
Genes 2024, 15(8), 982; https://doi.org/10.3390/genes15080982
Submission received: 20 June 2024 / Revised: 18 July 2024 / Accepted: 22 July 2024 / Published: 25 July 2024
(This article belongs to the Special Issue Molecular Epidemiology, Genome and Evolution of Viruses)
Browse Figure
Versions Notes

Abstract

:
The interaction of multiple viruses in one host is thought to enhance the development of mutations. However, the impact of hepatitis D virus (HDV) positivity on the development of unique hepatitis B virus (HBV) mutations among people living with human immunodeficiency virus (HIV) (PLWH) remains poorly understood in African countries, including Botswana. We used HBV sequences generated from the Botswana Combination Prevention Project (BCPP), which is the largest pair-matched cluster-randomized HIV trial in Botswana. Only participants with available HBV sequences (n = 55) were included in our study ([HIV/HBV-positive (n = 50) and HIV/HBV/HDV-positive (n = 5)]. Geno2pheno was used to determine HBV genotypes, and HBV surface region sequences (all subgenotype A1) were aligned in AliView for mutational analysis, while the impact of mutations was assessed using Phyre2. Our results identified 182 common mutations between the two groups. In the HIV/HBV/HDV cohort, only three mutations (L95W, W156Q, C221Y) were classified as deleterious, with only L95W being the most frequent. In the HIV/HBV cohort, four mutations (W199R, C221A, C221S, W223G) were also classified as deleterious. Our results demonstrate the presence of unique HBV mutations among the HIV/HBV/HDV-positive cohort. Functional characterization of these mutations is recommended to determine their effect on HDV.

1. Introduction

Approximately 15–20 million of the 254 million people living with chronic hepatitis B virus (HBV) are infected with hepatitis delta virus (HDV) [1], which translates to a prevalence of approximately 4.5% [2]. HDV is a satellite virus that depends on envelope proteins provided by HBV for successful replication; therefore, the highest burden of HDV is found in HBV-endemic regions such as Eastern and Mediterranean Europe, sub-Saharan Africa (SSA), and Central, Eastern and Northern Asia [3,4]. HDV/HBV co-infection or superinfection is the most severe form of chronic hepatitis. HDV co-infection is reported to significantly suppress HBV replication [5], while other studies have reported fluctuating or persistently high levels of HBV viral loads among HDV-positive patients [6,7]. HBV/HDV infection is associated with worse clinical outcomes among people living with human immunodeficiency virus (HIV)(PLWH), resulting in a higher incidence of cirrhosis, hepatocellular carcinoma (HCC), hepatic flares, decompensation, and increased mortality [8,9]. In the largest and most recent HDV study to date in Botswana, we reported an HDV prevalence of 7.1% among PLWH who were co-infected with HBV.
The hepatitis B surface gene encodes three viral proteins, namely the large hepatitis B surface antigen [(L-HBsAg) (PreS1, PreS2 and S)], middle-HBsAg (PreS2 and S) and the small-HBsAg (S) [10]. The HBV deoxyribonucleic acid (DNA) polymerase lacks proof-reading capabilities, leading to the development of mutations which drive the evolution of the HBsAg [11,12]. The host recognizes the HBsAg through the ‘a’ determinant region that is located between amino acids 124 and 147 of the HBsAg. This induces a protective humoral immune response [11,13,14]. Therefore, mutations in this region cause changes that have an impact on HBsAg antigenicity, resulting in the development of immune-escape mutations that negatively affect the clearance of HBV infection [15,16]. Interactions not only with HDV but also with other viruses can lead to an exertion of pressure on HBV, leading to the development of mutations. The presence of other viruses and the host’s immune response may act as cofactors that modulate the genetic variability and evolution of HBV [17]. A study on the impact of HIV on HBV mutations reported the presence of fewer BCP mutations (A1762T and G1764A) coupled with more PreS2 deletions among people with HIV/HBV co-infection than those with HBV mono-infection [18]. Meanwhile, co-infection with hepatitis C virus (HCV) was associated with a higher prevalence of A1762T/G1764A mutation and a lower prevalence of the A1752T/G, C1799G and G1896A mutations in the precore/core promoter region of people with HBV genotype C compared to genotype B [19]. It is very important to assess the potential impact of other co-infections on the detection of HBV mutations as they might have an impact on HBV pathogenesis. These studies suggest that the volume of HBV mutations may be virus- and genotype-specific; therefore, we need to curate data on the impact of HDV on the development of HBV mutations in the most prevalent genotype (A1) in Botswana.
The World Health Organization (WHO) has recommended that all PLWH should be tested for the presence of HBV prior to initiation of combination antiretroviral therapy (cART) and those with HBV should be initiated on approved cART with anti-HBV activity such as tenofovir, emtricitabine and entecavir [20]. Implementation of these guidelines in resource-limited countries such as Botswana remains a challenge partly due to a lack of a national hepatitis treatment program despite an advanced national HIV treatment program [21,22]. Poor adherence to these drugs can lead to the emergence of HBV drug resistance mutations (DRMs), resulting in limited HBV treatment options [23]. Therefore, the impact of HDV infection on the development of unique HBV mutations among PLWH remains poorly understood in Africa, including Botswana, where HBV and HDV are not routinely tested for. This study aimed to elucidate the potential impact of HDV infection on the development of HBV mutations among PLWH in Botswana.

2. Materials and Methods

2.1. Study Participants

This was a retrospective cross-sectional study utilizing HBV whole-genome sequences (n = 55) generated from participants of the Botswana Combination Prevention Project (BCPP) “Ya Tsie” trial (2013–2018). To date, BCPP remains the largest pair-matched cluster-randomized trial in Botswana which enrolled a total of 12,610 participants, among which 3596 were PLWH aged between 16 and 64 years from 30 communities in Botswana [24]. Half of the BCPP communities received the standard of care, while the remaining half of the communities received HIV prevention and treatment interventions [24].
The participants’ HIV testing history was collected during all visitations in the parent study and those without documented HIV-positive status were screened using HIV rapid tests (KHB, Shanghai Kehua Bio-Engineering, Shanghai, China, and Unigold, Trinity Biotech, Bray, Wicklow, Ireland). The HIV viral load was quantified in PLWH at baseline and final visits (Abbott RealTime HIV-1 Assay, Wiesbaden, Germany) and viral suppression was defined as an HIV-1 viral load of ≤400 copies/mL. Documentation of initiation of ART (e.g., prescriptions or pills, clinical notes) was required for classifying a participant as on ART, and a CD4 cell count (Pima, Alere, Waltham, MA, USA) was performed on PLWH who were not on ART [24].

2.2. HBV and HDV Screening

Participants chosen for this study were PLWH who had previously been screened for HBV markers using different enzyme-linked immunosorbent assays (ELISAs). These include HBsAg (Murex HBsAg Version 2 kit, Diasorin, Dartford, UK), hepatitis B e antigen (HBeAg) (Monolisa HBe Ag/Ab, Bio-Rad, Marnes-la-Coquette, France), total hepatitis B core antibodies (anti-HBc) (Monolisa anti-HBc PLUS kit, Bio-Rad, Marnes-la-Coquette, France) and hepatitis B core antibody immunoglobulin M (anti-HBc IgM) (Anti-HBc Plus 1 Plaque, Bio-Rad, Marnes-la-Coquette, France) according to the manufacturer’s instructions [25]. The HBV viral load was quantified among HBsAg-positive participants using the COBAS AmpliPrep/COBAS TaqMan HBV Test version 2.0 (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s instructions with a detection range from 20 to 1.7 × 108 IU/ mL. We screened residual samples from the parent study (stored at −80 °C) for anti-HDV antibodies at least once using the General Biologicals HDV Ab kit (General Biologicals Corporation, Taiwan, China), as per the manufacturer’s instructions. The Altona Diagnostic RealStar® HDV RT-PCR 1.0 detection kit was used to determine the HDV RNA load, with slight modifications in the manufacturer’s instructions as previously described [26].

2.3. HBV Sequence Diversity and Mutational Analysis

We used HBV full-genome sequences that were generated using the Oxford Nanopore sequencing technology in a previous study [27]. Briefly, DNA extraction was performed on HBV-positive plasma samples using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany), following the manufacturer’s instructions. This was followed by PCR of the HBV whole genome on the extracted DNA samples using the HBV tilling primer pool. Library preparation of the HBV whole-genome PCR amplicons was performed with the rapid barcoding and midnight expansion protocol (version MRT_9127_v110_revH_14 Jul 2021), using HBV primers. The GridION platform (Oxford Nanopore Technologies, Oxford, UK) was used to sequence the prepared HBV DNA library with version R9.4.1 flow cells (Oxford Nanopore Technologies, Oxford, UK).
The generated HBV sequences were aligned using AliView version 1.26 [28]. Geno2pheno [29] was used to determine HBV subgenotypes and mutations in the HBV surface region. The three domains of HBV surface proteins were manually extracted from an overlapping Pol/S fragment using the AliView version 1.26, and the impact of mutations in the S region was assessed using Phyre2 software [30]. The case group (HIV/HBV/HDV-positive) comprised participants with successfully generated HBV sequences (n = 5), all of whom were infected with HBV subgenotype A1. Only HBV subgenotype A1 sequences (n = 50) from the control group (HIV/HBV positive) were selected for diversity and mutational analysis (Figure 1).

3. Results

3.1. Participants Demographics

From participants who were HBV-positive (n = 271), only those with successfully generated HBV sequences (n = 55) were selected for this study. These participants were stratified into HIV/HBV-positive (n = 50) and HIV/HBV/HDV-positive (n = 5) groups, as shown in Table 1. HIV/HBV/HDV-positive participants, all of whom were infected with HDV clade 8, tested negative for HBeAg and anti-HBc IgM. All HIV/HBV/HDV-positive participants had an HBV viral load <2000 IU/mL compared to 72% (36/50) of HIV/HBV-positive participants.

3.2. Mutational Frequency and Potential Effect

HBsAg mutational analysis revealed a total of 615 mutations from both groups. Of these, there were 403 unique mutations from participants who were HIV/HBV-positive, 30 unique mutations were from HIV/HBV/HDV (L95W, V96D, P105H, C138A, W156Q, K160N, Y161F, F183S, V184G)-positive participants, and 182 mutations were common between the two groups (F8L, T57I, T114S, E164D, V180A, A194V, I195M, S207N and P214L). Among the common mutations, S207N (36.2%), A194V (34.6%) and I195M (19.8%) had the highest frequency.
Our findings also showed a high prevalence of mutations S207N (10.6%), A194V (10.1%), I195M (5.9%), E164D (2.8%) and K122R (1.4%) among HIV/HBV-positive participants, with none of them exhibiting any deleterious effect. Mutations that exhibited a deleterious effect from this group include W199R, C221A, C221S and W223G. Mutations with the highest prevalence in the HIV/HBV/HDV-positive group include S207N (11.8%), A194V (11.8%) and I195M (5.9%), albeit with non-deleterious effects. Only mutations L95W, W156Q and C221Y were found to have deleterious effects in this group. All these mutations occurred in one participant whose HBV viral load was 409 IU/mL and who was receiving efavirenz, emtricitabine and tenofovir as HIV antiretroviral therapy (Table 2).
Only one mutation (C138A) was recorded in the ‘a’ determinant region of HBV sequences from individuals with HIV/HBV/HDV, while three mutations were recorded in HBV sequences from individuals with HIV/HDV. Additionally, five (5) mutations were recorded in the HBsAg C terminus region (aa204–206) of HBV sequences from people with HIV/HBV, while none were recorded in the HIV/HBV/HDV cohort.

4. Discussion

This is the first study to report on the impact of HDV infection on the development of unique HBV mutations among PLWH in Botswana. We had a total of 55 participants with HBV subgenotype A1. This is not surprising because HBV subgenotype A1 is the most prevalent strain that is circulating in Botswana [31]. None of the HIV/HBV/HDV-positive participants were positive for HBeAg or IgM anti-HBc-positive serology markers, respectively. Additionally, none of the HIV/HBV/HDV-positive participants had an HBV viral load ≥2000 IU/mL compared to 28% (14/50) of HIV/HBV-positive participants. These results are surprising because according to the literature, HIV/HBV/HDV infection is associated with severe hepatitis, which is signified by elevated HBV viral load, resulting in rapid progression to liver-related complications and mortality compared to HIV/HBV infection [8,9]. Alternatively, the low HBV viral load among participants with HIV/HBV/HDV could be attributed to the high HDV viral load coupled with the low HBV viral load observed in 60% of those participants as HDV tends to be the more dominant virus.
Several unique mutations recorded in the HIV/HBV/HDV cohort such as L95W and Y161F have previously been reported in chronic HBV liver disease patients with unknown HIV and HDV status [32]. However, this study did not elucidate their potential clinical significance on chronic HBV progression to hepatocellular carcinoma. The fact that these two mutations have previously been detected in a study without documented HDV positivity makes it difficult for us to attribute their presence or frequency to HDV positivity in our study. Substitutions in the ‘a’ determinant region of the major hydrophilic loop may lead to defective antigenicity and detection of HBsAg in the process compromising diagnosis and protection against HBV infection [33]. We report low genetic variability in the ‘a’ determinant region (located between amino acids 124 and 147) of HIV/HBV/HDV-positive participants, with only the C138A mutation, which was a polymorphism, seen in this region. The disulfide bonds of the cysteine residues in the antigenic loop (AGL) are critical for both the structure of the “a” determinant and reduction in HDV infectivity. The inhibition of the disulfide exchange reactions is associated with reduced HDV infectivity, which favors HBV dominance over HDV [34]. Cysteine substitutions in the AGL, including the C138A mutation, have previously been associated with decreased antigenicity and severely limit the binding of HBV to B- or T-cell receptors during cell-mediated immune responses [34]. This makes it harder for the host to successfully eliminate HBV, leading to the development of chronic HBV infections. We could not find any literature reports documenting the other mutations found in the HIV/HBV/HDV cohort, so they could be unique to this cohort and their potential clinical significance remains to be determined.
However, cysteine was substituted with alanine, leading to proteasomal damage in this position (Table 1). A previous study reported an increased rate of degradation after the substitution of cysteine with lysine residues in the HBV envelope protein [35]; therefore, proteasomal degradation due to alanine is a rare occurrence that needs to be studied further.
Mutations found in the ‘a’ determinant region of HIV/HBV-positive participants include N131T, C139R and T140I (immune escape), all of which were polymorphisms that have not been associated with proteasomal degradation in these positions. Mutations in the HBsAg C terminus region (located in amino acids 204 and 206) are detrimental to HDV replication [36]. However, in our study, position 204 was conserved, while mutations were found in position 206 (substitution of histidine and arginine in place of tyrosine) in the HIV/HBV-positive group but none were found in the HIV/HBV/HDV cohort. Deletions at positions 179 to 183, 194 to 198 and 199 to 203 of HBsAg are primarily associated with inhibition of HDV assembly [37]. Furthermore, these sites are reported to be crucial for the amplification of HBV mutations that counteract the inhibitory effects of HDV on HBV replication. No deletions were observed in our study but several mutations from both groups were found in this region. We also identified the W199R deleterious mutation (arginine instead of tryptophan) in the HIV/HBV-positive group, which resulted in proteasomal degradation, as well as the P203L mutation. Other important mutations linked with immune escape that were found outside the ‘a’ determinant region include the K122R mutation, which was detected among HIV/HBV-positive participants, and the S207N mutation, which was detected with a high frequency in both cohorts.
This study was limited by having few HDV/HBV/HIV-positive participants, which hindered comparisons using a larger cohort. The other limitation is that all participants had HBV subgenotype A1 and HDV clade 8; therefore, our findings might not necessarily be applicable to other HBV and HDV genotypes. We did not have clinical data of study participants such as fibrosis, liver enzyme levels and liver disease staging data to elucidate how they are potentially affected by HBV mutations.

5. Conclusions

In conclusion, our results demonstrate the presence of unique HBV mutations among the HIV/HBV/HDV-positive cohort. However, we need to study these mutations in a cohort with only HBV/HDV infection to confirm that they are solely associated with HDV infection. Interestingly, we report the presence of the C138A mutation which is associated with low HBV antigenicity and reduced HDV infectivity. Functional characterization of the other HBV mutations identified is recommended to determine their effect on HDV.

Author Contributions

Conceptualization, K.B., M.A., S.M., M.J. and S.G.; methodology, K.B., M.A., W.T.C. and S.G.; validation, W.T.C. and L.B.; formal analysis, K.B., B.B.P. and W.T.C.; investigation, K.B., B.P. and P.C.M.; resources, B.B.P., M.A., M.J., S.M. and S.G.; data curation, K.B., B.B.P., B.P., W.T.C. and G.G.A.M.; writing—original draft preparation, K.B.; writing—review and editing, B.P., B.B.P., P.C.M., M.A., M.J., W.T.C., T.R., B.P., G.G.A.M., S.M. and S.G.; visualization, B.B.P. and T.R.; supervision, M.A., M.J., S.M. and S.G.; project administration, K.B.; funding acquisition, M.A., S.M., M.J. and S.G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Wellcome Trust (grant number 218770/Z/19/Z). Wonderful T. Choga, Sikhulile Moyo and Simani Gaseitsiwe are partly supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE 2.0) from the Bill & Melinda Gates Foundation (INV-033558). Kabo Baruti, Bonolo Phinius, Motswedi Anderson, and Simani Gaseitsiwe are supported by the Fogarty International Center at the US National Institutes of Health Award D43 TW009610. Wonderful Choga, Motswedi Anderson and Simani Gaseitsiwe are supported partly by NIH (award number 1G11TW012503-01). Bonolo B. Phinius was partially supported by Trials of Excellence in Southern Africa (TESAIII), which is part of the EDCTP2 program supported by the European Union (grant number CSA2020NoE-3104 TESAIII. Motswedi Anderson received support from SANTHE PTI009. Sikhulile Moyo received support from the NIH Fogarty International Center Award K43TW012350. BCPP was funded by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and sponsored through the Centers for Disease Control and Prevention (CDC) under cooperative agreements U01 GH000447 and U2G GH001911. The views expressed in this publication are those of the authors and not necessarily those of the European Union, EDCTP, NIH, Bill & Melinda Gates Foundation, Africa Academy of Sciences or the UK government. The funders had no role in the study design, data collection, decision to publish, or the preparation of the manuscript.

Institutional Review Board Statement

The study received ethical clearance from the University of Botswana (UB) ethics review committee and was granted a research permit (HPDME 6/14/1) from the Health Research Development Committee (HRDC) of the Botswana Ministry of Health (MoH).

Informed Consent Statement

The study participants signed informed written consent for participation in the parent study, and for storage and usage of residual samples in future studies.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author. The data are not publicly available as the sequences are currently being analyzed for other objectives of the bigger project.

Acknowledgments

We thank the study participants, dikgosi and other community leaders, members of the Ya Tsie community advisory board, and the clinic staff and district health management teams at all study sites, the Ya Tsie Study Team at the Botswana Harvard Health Partnership, the Harvard TH Chan School of Public Health, the Centers for Disease Control and Prevention, and the Botswana Ministry of Health. We would also like to acknowledge those who served on the Ya Tsie Community Advisory Board, Laboratory Staff, and Management of Botswana Harvard HIV Reference Laboratory.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization. Hepatitis Delta Virus Fact Sheet. 2023. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d (accessed on 20 February 2024).
  2. Stockdale, A.J.; Kreuels, B.; Henrion, M.Y.; Giorgi, E.; Kyomuhangi, I.; de Martel, C.; Hutin, Y.; Geretti, A.M. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J. Hepatol. 2020, 73, 523–532. [Google Scholar] [CrossRef] [PubMed]
  3. Béguelin, C.; Moradpour, D.; Sahli, R.; Suter-Riniker, F.; Lüthi, A.; Cavassini, M.; Günthard, H.F.; Battegay, M.; Bernasconi, E.; Schmid, P.; et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J. Hepatol. 2017, 66, 297–303. [Google Scholar] [CrossRef] [PubMed]
  4. Hayashi, T.; Takeshita, Y.; Hutin, Y.J.-F.; Harmanci, H.; Easterbrook, P.; Hess, S.; van Holten, J.; Oru, E.O.; Kaneko, S.; Yurdaydin, C.; et al. The global hepatitis delta virus (HDV) epidemic: What gaps to address in order to mount a public health response? Arch. Public Health 2021, 79, 180. [Google Scholar] [CrossRef]
  5. Arribas, J.R.; González-García, J.J.; Lorenzo, A.; Montero, D.; de Guevara, C.L.; Montes, M.; Hernández, S.; Pacheco, R.; Peña, J.M.; Vázquez, J.J. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005, 19, 1361–1365. [Google Scholar] [CrossRef]
  6. Hughes, S.A.; Wedemeyer, H.; Harrison, P.M. Hepatitis delta virus. Lancet 2011, 378, 73–85. [Google Scholar] [CrossRef]
  7. Shirvani-Dastgerdi, E.; Tacke, F. Molecular interactions between hepatitis B virus and delta virus. World J. Virol. 2015, 4, 36–41. [Google Scholar] [CrossRef]
  8. Fernández-Montero, J.V.; Vispo, E.; Barreiro, P.; Sierra-Enguita, R.; de Mendoza, C.; Labarga, P.; Soriano, V. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin. Infect. Dis. 2014, 58, 1549–1553. [Google Scholar] [CrossRef]
  9. Katwesigye, E.; Seremba, E.; Semitala, F.; Ocama, P. Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda. Afr. Health Sci. 2017, 17, 974–978. [Google Scholar] [CrossRef] [PubMed]
  10. Kuo, M.; Tseng, P.; Chou, Y.; Chang, K.; Tsai, M.; Kuo, Y.; Hu, T.; Hung, C.; Wang, J.; Lu, S.; et al. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J. Gastroenterol. Hepatol. 2018, 33, 1766–1772. [Google Scholar] [CrossRef]
  11. Churin, Y.; Roderfeld, M.; Roeb, E. Hepatitis B virus large surface protein: Function and fame. HepatoBiliary Surg. Nutr. 2015, 4, 1–10. [Google Scholar] [CrossRef]
  12. Bertoletti, A.; Ferrari, C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003, 38, 4–13. [Google Scholar] [CrossRef] [PubMed]
  13. Cao, J.; Luo, S.; Xiong, Y. The Variability of Amino Acid Sequences in Hepatitis B Virus. Virol. Sin. 2019, 34, 42–49. [Google Scholar] [CrossRef] [PubMed]
  14. Howard, C.R.; Allison, L.M. Hepatitis B surface antigen variation and protective immunity. Intervirology 1995, 38, 35–40. [Google Scholar] [CrossRef] [PubMed]
  15. Lazarevic, I. Clinical implications of hepatitis B virus mutations: Recent advances. World J. Gastroenterol. 2014, 20, 7653–7664. [Google Scholar] [CrossRef] [PubMed]
  16. Caligiuri, P.; Cerruti, R.; Icardi, G.; Bruzzone, B. Overview of hepatitis B virus mutations and their implications in the management of infection. World J. Gastroenterol. 2016, 22, 145–154. [Google Scholar] [CrossRef] [PubMed]
  17. Li, K.-W.; Kramvis, A.; Liang, S.; He, X.; Chen, Q.-Y.; Wang, C.; Yang, Q.-L.; Hu, L.-P.; Jia, H.-H.; Fang, Z.-L. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults. Virus Res. 2017, 227, 88–95. [Google Scholar] [CrossRef] [PubMed]
  18. Audsley, J.; Littlejohn, M.; Yuen, L.; Sasadeusz, J.; Ayres, A.; Desmond, C.; Spelman, T.; Lau, G.; Matthews, G.V.; Avihingsanon, A.; et al. HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology 2010, 405, 539–547. [Google Scholar] [CrossRef] [PubMed]
  19. Hung, C.-H.; Chen, C.-H.; Lu, S.-N.; Wang, J.-H.; Hu, T.-H.; Huang, C.-M.; Tsai, M.-C.; Lee, C.-M. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. Antivir. Res. 2012, 93, 55–63. [Google Scholar] [CrossRef]
  20. Organisation, W.H. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015. Available online: https://www.who.int/publications-detail-redirect/9789241549059 (accessed on 10 January 2024).
  21. Belyhun, Y.; Maier, M.; Liebert, U.G. HIV Therapy with Unknown HBV Status is Responsible for Higher Rate of HBV Genome Variability in Ethiopia. Antivir. Ther. 2016, 22, 97–111. [Google Scholar] [CrossRef]
  22. Chambal, L.M.; Gudo, E.S.; Carimo, A.; Real, R.C.; Mabunda, N.; Maueia, C.; Vubil, A.; Zicai, A.F.; Bhatt, N.; Antunes, F. HBV infection in untreated HIV-infected adults in Maputo, Mozambique. PLoS ONE 2017, 12, e0181836. [Google Scholar]
  23. Warner, N.; Locarnini, S. Mechanisms of hepatitis B virus resistance development. Intervirology 2014, 57, 218–224. [Google Scholar] [CrossRef] [PubMed]
  24. Wirth, K.E.; Gaolathe, T.; Holme, M.P.; Mmalane, M.; Kadima, E.; Chakalisa, U.; Manyake, K.; Mbikiwa, A.M.; Simon, S.V.; Letlhogile, R.; et al. Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): A cluster-randomised trial. Lancet HIV 2020, 7, e422–e433. [Google Scholar] [CrossRef] [PubMed]
  25. Phinius, B.B.; Anderson, M.; Gobe, I.; Mokomane, M.; Choga, W.T.; Mutenga, S.R.; Mpebe, G.; Pretorius-Holme, M.; Musonda, R.; Gaolathe, T.; et al. High Prevalence of Hepatitis B Virus Infection among People with HIV in Rural and Periurban Communities in Botswana. Open Forum Infect. Dis. 2023, 10, ofac707. [Google Scholar] [CrossRef]
  26. Baruti, K.; Phinius, B.B.; Phakedi, B.; Mpebe, G.; Choga, W.; Bhebhe, L.; Mulenga, G.; Moraka, N.O.; Ratsoma, T.; Pretorius-Holme, M.; et al. High prevalence of hepatitis delta virus among people with hepatitis B virus and HIV coinfection in Botswana. J. Infect. Public Health 2023, 16, 1736–1741. [Google Scholar] [CrossRef] [PubMed]
  27. Phinius, B.B.; Anderson, M.; Mokomane, M.; Gobe, I.; Choga, W.T.; Ratsoma, T.; Phakedi, B.; Mpebe, G.; Ditshwanelo, D.; Musonda, R.; et al. Atypical Hepatitis B Virus Serology Profile—Hepatitis B Surface Antigen-Positive/Hepatitis B Core Antibody-Negative—In Hepatitis B Virus/HIV Coinfected Individuals in Botswana. Viruses 2023, 15, 1544. [Google Scholar] [CrossRef] [PubMed]
  28. Larsson, A. AliView: A fast and lightweight alignment viewer and editor for large datasets. Bioinformatics 2014, 30, 3276–3278. [Google Scholar] [CrossRef] [PubMed]
  29. Geno2pheno (hbv) v2.0. Available online: https://hbv.geno2pheno.org/ (accessed on 23 May 2024).
  30. Kelley, L.A.; Mezulis, S.; Yates, C.M.; Wass, M.N.; Sternberg, M.J.E. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 2015, 10, 845–858. [Google Scholar] [CrossRef] [PubMed]
  31. Anderson, M.; Gaseitsiwe, S.; Moyo, S.; Wessels, M.J.C.; Mohammed, T.; Sebunya, T.K.; Powell, E.A.; Makhema, J.; Blackard, J.T.; Marlink, R.; et al. Molecular characterisation of hepatitis B virus in HIV-1 subtype C infected patients in Botswana. BMC Infect. Dis. 2015, 15, 335. [Google Scholar] [CrossRef] [PubMed]
  32. Huong, N.T.C.; Trung, N.Q.; Luong, B.A.; Tram, D.B.; Vu, H.A.; Bui, H.H.; Le, H.P.T. Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients. PLoS ONE 2022, 17, e0266134. [Google Scholar] [CrossRef]
  33. Cui, Y.; Zhang, T.; Yan, Y.; Liu, K. Identification of a mutation in Hepatitis B virus surface antigen capable of evading ELISA screening. Genet. Mol. Res. 2016, 15, gmr.15037582. [Google Scholar] [CrossRef]
  34. Abou-Jaoudé, G.; Sureau, C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J. Virol. 2007, 81, 13057–13066. [Google Scholar] [CrossRef] [PubMed]
  35. Liu, Y.; Testa, J.S.; Philip, R.; Block, T.M.; Mehta, A.S. A Ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation. PLoS ONE 2011, 6, e24477. [Google Scholar] [CrossRef] [PubMed]
  36. Colagrossi, L.; Salpini, R.; Scutari, R.; Carioti, L.; Battisti, A.; Piermatteo, L.; Bertoli, A.; Fabeni, L.; Minichini, C.; Trimoulet, P.; et al. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses 2018, 10, 363. [Google Scholar] [CrossRef] [PubMed]
  37. Jenna, S.; Sureau, C. Mutations in the carboxyl-terminal domain of the small hepatitis b virus envelope protein impair the assembly of hepatitis delta virus particles. J. Virol. 1999, 73, 3351–3358. [Google Scholar] [CrossRef]
Genes 15 00982 g001
Figure 1. Summary flow chart of samples tested in the study.
Figure 1. Summary flow chart of samples tested in the study.
Genes 15 00982 g001
Table 1. Demographics and clinical characteristics.
Table 1. Demographics and clinical characteristics.
CharacteristicHIV/HBV
Positive (n = 50)		HIV/HBV/HDV Positive (n = 5)
Male n (%)21 (42)2 (40)
Median Age [IQR]42 [36–48]46 [41–46]
HIV viral load n (%)
Suppressed47 (94)5 (100)
Not suppressed2 (4)0
Unspecified1 (2)0
ART Status n (%)
On ART48 (96)5 (100)
Naïve1 (2)0
Unspecified1 (2)0
ART regimen n (%)
TDF-containing regimen21 (42)4 (80)
3TC-containing regimen15 (30)1 (20)
Unspecified14 (28)0
ARV duration in years, median (IQR)7.9 [4.2–10.2]5.2 [5.1–5.5]
HBV viral load n (%)
Target not detected12 (24)1 (20)
<2000 IU/mL24 (48)4 (80)
≥2000 IU/mL14 (28)0
HBeAg positivity, n (%)9 (18)0
Anti-HBc positivity, n (%)43 (86)5 (100)
IgM anti-HBc positivity, n (%)3 (6)0
Marital status, n (%)
Single or never married35 (70)4 (80)
Married, divorced, separated or widowed14 (28)1 (20)
Unspecified1 (2)0
Education, n (%)
Non-formal and primary24 (48)3 (60)
Junior secondary education or higher25 (50)2 (40)
Unspecified1 (2)0
HDV—hepatitis D virus; HIV—human immunodeficiency virus; IQR—interquartile range; HBV—hepatitis B virus; HBeAg—hepatitis B e antigen; IgM anti-HBc—immunoglobulin M antibody to hepatitis B core antigen; Anti-HBc—hepatitis B core antibody; ARV—antiretrovirals; ART—antiretroviral therapy.
Table 2. Amino acid substitutions and their potential effect.
Table 2. Amino acid substitutions and their potential effect.
Wild-Type Amino AcidAmino acid Substitutions
(HIV/HBV/
HDV+)		Mutational SensitivityEffectAmino acid Substitutions
(HIV/HBV+)		Mutational SensitivityEffect
N3---G(2%), S(4%)LowPolymorphism
G7---G(2%)LowPolymorphism
F8L(20%)LowPolymorphismL(2%)LowPolymorphism
R24---K(4%)MediumPolymorphism
L26---P(2%)MediumPolymorphism
S45---T(2%), A(8%)LowPolymorphism
P46---T(2%)LowPolymorphism
P56---L(2%)LowPolymorphism
T57I(20%)LowPolymorphismI(6%)LowPolymorphism
P62---S(2%)LowPolymorphism
L95W(20%)HighDeleterious---
V96D(20%)MediumPolymorphismA(11%)MediumPolymorphism
Q101---K(2%)LowPolymorphism
P105H(20%)LowPolymorphism---
T114S(20%)LowPolymorphismS(4%)LowPolymorphism
K122---R(15%)LowPolymorphism
N131---T(2%)LowPolymorphism
C138A(20%)LowPolymorphism---
C139---R(2%)MediumPolymorphism
T140---I(2%)LowPolymorphism
W156Q(20%)HighDeleterious---
A159---I(2%) Polymorphism
K160N(20%)LowPolymorphism---
Y161F(20%)LowPolymorphism---
E164D(60%)LowPolymorphismD(30%)LowPolymorphism
A166---D(2%)MediumPolymorphism
V180A(20%)LowPolymorphismA(8%)LowPolymorphism
F183S(20%)MediumPolymorphism---
V184G(20%)LowPolymorphismW(2%), A(2%), R(2%)LowPolymorphism
G185---W(2%)LowPolymorphism
P188L(20%)MediumPolymorphismL(2%)LowPolymorphism
V190---I(2%)MediumPolymorphism
V194---A(2%)LowPolymorphism
I195M(60%)LowPolymorphismM(55%)LowPolymorphism
M198---V(2%)LowPolymorphism
W199---R(4%)HighDeleterious
P203---L(2%), Q(4%) MediumPolymorphism
L205---Q(2%), C(2%), S(2%)MediumPolymorphism
Y206---H(4%), R(6%)MediumPolymorphism
S207N(12%)MediumPolymorphismN(2%)MediumPolymorphism
I213---M 2%)MediumPolymorphism
P214---L(4%)MediumPolymorphism
L215---P(2%)MediumPolymorphism
C221Y(20%)HighDeleteriousA(2%)HighDeleterious
W223---G(2%)HighDeleterious
HDV—hepatitis D virus; HIV—human immunodeficiency virus; HBV—hepatitis B virus; A—alanine; C—cysteine; D—aspartic acid; E—glutamic acid; F—phenylalanine; G—glycine; H—histidine; I—isoleucine; K—lysine; L—leucine; M—methionine; N—asparagine; P—proline; Q—glutamine; R—arginine; S—serine; T—threonine; W—tryptophan; Y—tyrosine; V—valine.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Baruti, K.; Choga, W.T.; Phinius, B.B.; Phakedi, B.; Bhebhe, L.; Mpebe, G.G.A.; Motshosi, P.C.; Ratsoma, T.; Moyo, S.; Jongman, M.; et al. Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations. Genes 2024, 15, 982. https://doi.org/10.3390/genes15080982

AMA Style

Baruti K, Choga WT, Phinius BB, Phakedi B, Bhebhe L, Mpebe GGA, Motshosi PC, Ratsoma T, Moyo S, Jongman M, et al. Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations. Genes. 2024; 15(8):982. https://doi.org/10.3390/genes15080982

Chicago/Turabian Style

Baruti, Kabo, Wonderful T. Choga, Bonolo B. Phinius, Basetsana Phakedi, Lynnette Bhebhe, Gorata G. A. Mpebe, Patience C. Motshosi, Tsholofelo Ratsoma, Sikhulile Moyo, Mosimanegape Jongman, and et al. 2024. "Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations" Genes 15, no. 8: 982. https://doi.org/10.3390/genes15080982

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop